NCT04006301: First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

NCT04006301
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have KRAS G12C mutation in tumor tissue or blood; Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: Patients with symptomatic unstable brain metastases or known leptomeningeal disease that require treatment – see trial for details
https://ClinicalTrials.gov/show/NCT04006301

Comments are closed.

Up ↑